Business Context and Reporting Period
This Form 8-K Current Report for MEDIFAST INC covers events occurring on May 19, 2026, specifically the Company's 2026 Annual Meeting of Stockholders, and subsequent executive appointments effective June 1, 2026. The filing details corporate governance actions, including the election of directors, ratification of auditors, and significant changes to executive leadership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance results.
Material Changes and Executive Leadership
- CEO Transition: Daniel Chard, current Chairman and CEO, will transition to the role of non-executive Chairman effective June 1, 2026. The transition is not due to any disagreement with management or the Board.
- New CEO Appointment: Nicholas Johnson, age 46, was appointed Chief Executive Officer, effective June 1, 2026. Mr. Johnson has been with Medifast since 2018, most recently serving as President.
- Compensation Package: Mr. Johnson's offer letter includes:
- Annual base salary of $600,000.
- Target bonus of 100% of base salary.
- Long-term incentive target of 250% of base salary.
- Total compensation represents an approximate 69% increase compared to his prior role as President.
Stockholder Votes and Corporate Actions
At the Annual Meeting on May 19, 2026, stockholders approved the following proposals:
- Director Elections: All seven nominated directors were elected. Notable vote counts included Scott Schlackman, who received 795,603 "Against" votes, significantly higher than other nominees.
- Auditor Ratification: Stockholders approved the appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (6,411,175 For vs. 53,444 Against).
- Executive Compensation: The advisory vote on named executive officer compensation was approved (3,996,046 For vs. 637,173 Against).
- Share Incentive Plan: Stockholders approved an amendment to the 2012 Share Incentive Plan to increase the authorized share count by 250,000 shares. This proposal received 3,195,078 "For" votes and 1,442,997 "Against" votes.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 99.1) to confirm specific vesting schedules and termination provisions for Nicholas Johnson.
- Review the Amended and Restated 2012 Share Incentive Plan (Exhibit 10.1) to understand the impact of the 250,000 share increase on dilution.
- Monitor the transition period starting June 1, 2026, to assess operational continuity as Daniel Chard moves to a non-executive role.
- Examine the "Against" vote totals for the Share Incentive Plan and specific directors to gauge stockholder sentiment regarding compensation and governance.